Gene Therapy Explained: AAV, Lentiviral Vectors, Luxturna, and Zolgensma

One Drug. $2.1 Million. One Injection. Potentially Lifelong.

Zolgensma (onasemnogene abeparvovec), approved by the FDA in May 2019 for spinal muscular atrophy type 1 (SMA1), is the most expensive drug in history by single-dose price. It costs approximately $2.1 million per treatment in the United States. SMA1 is caused by mutations in the SMN1 gene, leading to degeneration of motor neurons and death or ventilator dependence in most affected infants before age 2. A single intravenous injection of Zolgensma delivers a functional copy of SMN1 into motor neuron cells via an adeno-associated virus (AAV9) vector. In the pivotal trial, 100% of treated infants (vs. a natural history cohort) were alive without ventilation at 24 months, and most achieved motor milestones including sitting unsupported. Gene therapy had arrived as a clinical reality. The price reflects not just development costs but the extreme rarity of the disease and the cost of manufacturing — currently one of the most technically complex biological manufacturing processes in existence.

Delivery Systems: Three Vectors, Three Tradeoffs

Getting a therapeutic gene into the right cells — and keeping it there — requires a delivery vehicle (vector). The three main classes represent fundamentally different biological strategies.

AAV: The Gene Therapy Workhorse

Adeno-associated viruses are small, non-pathogenic parvoviruses that have evolved to enter cells efficiently without causing disease in humans. Recombinant AAV (rAAV) vectors retain the AAV capsid — which determines which tissues the vector targets (serotype tropism) — and replace the viral genome with the therapeutic gene plus a promoter. AAV does not typically integrate into the host chromosome; the therapeutic DNA persists as an episome (circular DNA) in the cell nucleus. This has critical implications: in non-dividing cells like neurons and cardiomyocytes, episomal AAV persists long-term and can produce sustained therapeutic benefit. In rapidly dividing cells (like liver hepatocytes in growing children), the episome is diluted with each cell division — which is why Zolgensma's durability in growing infants is a genuine long-term concern, and why older patients (whose cells divide more slowly) may have better durability.

• AAV9 crosses the blood-brain barrier efficiently, making it the preferred serotype for neurological diseases including SMA and some lysosomal storage disorders.
• AAVrh10, AAV2, AAV5, and AAV8 are used for different tissue tropisms (retinal pigment epithelium, liver, muscle, respectively).
• Pre-existing anti-AAV antibodies from natural childhood exposure to wild-type AAV variants exclude approximately 30–50% of adult patients from AAV gene therapy trials — a major access barrier.

Luxturna: Restoring Vision with a $850,000 Drug

Luxturna (voretigene neparvovec, Spark Therapeutics) was the first FDA-approved in vivo gene therapy for a genetic disease, approved in December 2017. It treats inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations — a rare condition causing progressive blindness from childhood. Luxturna delivers a functional RPE65 gene directly into retinal pigment epithelium cells via subretinal injection of AAV2 vector. The procedure is performed in one eye at a time to preserve the second eye as a safety backup. Clinical trials showed sustained improvement in light sensitivity and visual function (measured by multi-luminance mobility testing) for at least 4 years post-treatment. The list price of $850,000 per eye ($425,000 per eye) was negotiated with insurers using an outcomes-based payment model — one of the first applications of pay-for-performance to gene therapy pricing.

Ex Vivo vs. In Vivo: A Fundamental Strategic Choice

Gene therapy approaches divide into two delivery strategies that differ in where the genetic modification occurs.

• In vivo gene therapy: The vector is directly injected into the patient — intravenously, intrathecally, subretinally, or intramuscularly — and must find and enter the target cells within the body. Simpler from a process standpoint but requires highly tissue-specific vector tropism and faces immune challenges. Luxturna and Zolgensma are in vivo therapies.
• Ex vivo gene therapy: Target cells (typically blood stem cells or T cells) are harvested from the patient, modified in the laboratory with a lentiviral or AAV vector, and then re-infused. Allows extensive quality control and genetic verification before administration. CAR-T therapies (Kymriah, Yescarta) and stem cell gene therapies for sickle cell disease (Casgevy — the first CRISPR drug, approved 2023) use this approach.

Durability: The Unanswered Question

Gene therapy's promise is lifetime benefit from a single treatment. The reality is more nuanced. AAV episomes are diluted by cell division; lentiviral integration carries rare but real insertional mutagenesis risk; immune responses can destroy transduced cells. Long-term durability data is limited by the recency of approvals:

Manufacturing: The Bottleneck Nobody Discusses

Gene therapy manufacturing is extraordinarily complex. AAV production requires mammalian cell culture (typically HEK293 cells), viral packaging, multi-step chromatographic purification, and extensive quality testing for empty capsids (AAV shells without therapeutic cargo, which trigger immune responses), aggregates, and adventitious agents. Global manufacturing capacity is severely limited: only a handful of facilities worldwide can produce clinical-grade AAV at commercial scale. This scarcity is a primary driver of high pricing — and a genuine barrier to expanding access even when insurance coverage is secured. Major pharmaceutical companies including Novartis, Roche, and Pfizer have invested billions in dedicated gene therapy manufacturing infrastructure since 2019, but capacity expansion takes 5–7 years to bring online.